Tech

Upstream Bio's verekitug cuts asthma attacks 56% in Phase 2

Upstream Bio reported Phase 2 VALIANT data showing verekitug cut asthma attacks by 56% at the 100 mg q12w dose, with FeNO and lung-function signals supporting a robust inflammatory biomarker response. The company says it plans registrational trials in severe asthma and CRSwNP, signaling near-term catalysts and potential partnerships.

📅 February 11, 2026
⏱️ 2 min read
Upstream Bio's verekitug cuts asthma attacks 56% in Phase 2

Key Takeaways

  • Phase 2 VALIANT shows 56% AAER reduction at 100 mg q12w; 39% at 400 mg q24w; 100 mg biannual significant for AAER but weaker on other endpoints.
  • FeNO at week 60 fell 20.4 ppb (100 mg q12w) and 26.3 ppb (400 mg q24w) with highly significant p-values, and baseline reductions of ~43.5% and 44.9%.
  • Verekitug was well-tolerated; most eligible patients advanced to a long-term extension.
  • Near-term catalysts include registrational trials in severe asthma and CRSwNP, potential partnerships, and VIBRANT CRSwNP topline results, with several analysts initiating Outperform ratings (targets around $40-$51).

People Involved

  • No specific individuals mentioned

Entities Involved

  • Upstream BioBiotechnology company developing verekitug
  • MizuhoEquity research firm/analyst coverage on UPB
  • LifeSci CapitalEquity research firm covering life sciences
  • Evercore ISI GroupInvestment bank with equity research coverage

MarketMoodz Analysis

For investors, VALIANT data imply a meaningful reduction in asthma exacerbations and robust biomarker signals that could differentiate verekitug in a crowded severe asthma space. If regulators advance registrational trials and global approvals are secured, the program could become a multi-indication platform with partnership opportunities.

Historically, phase 2 successes rarely translate to phase 3 outcomes, and the competitive landscape for severe asthma features entrenched biologics with established safety and efficacy profiles. Positive signals in CRSwNP from VIBRANT add optionality, but topline results remain unverified; real-world outcomes and cost considerations will shape adoption.

Watch for regulatory interactions that unlock registrational trial timelines, any licensing deals tied to severe asthma or CRSwNP, and readouts from real-world data post-approval to gauge durability of benefits and payer acceptance.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial